S-Benzyl-N-(S-Benzyl-2-Mercapto-2-Methylpropanoyl)-L-Cysteine置于氨,Sodium体系中,用81%的收率获得产物布溪那明 参考文献:Thiol Compounds. Ii. Synthesis And Antihypertensive Activity Of Mercaptoacylamino Acids. 标题:Thiol Compounds. Ii. Synthesis And Antihypertensive Activity Of Mercaptoacylamino Acids. 摘要:本文描述了一系列巯基氨基酸的合成和结构-活性关系.对这些化合物进行了抗高血压活性测试.在将这些化合物作为血管紧张素 I 转换酶抑制剂进行体外筛选时,发现 N-(2-巯基丙酰基)-L-半胱氨酸-A(7A)和 N2-(2-巯基丙酰基)-L-色氨酸-A(20A)的活性分别是硫普罗宁的 10 倍和 20 倍. DOI:10.1248/cpb.29.940
专利号:CN-1425662-A 优先权日:2002-12-23 标题:Synthesis of new intermediate 5,5-dimethyl-2-thione-4-one-1-thio-3-oxo-oxolane in the synthesis of Bucillamine
专利号:US-11993606-B2 优先权日:2015-10-16 标题:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 发明人:MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; PANGAN AILEEN L; SONG IN-HO; KLÜNDER BEN; VOSS JEFFREY W; PADLEY ROBERT J; CAMP HEIDI S 权利人:ABBVIE INC 摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
专利号:US-11512092-B2 优先权日:2015-10-16 标题 :Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 发明人:ALLIAN AYMAN; JAYANTH JAYANTHY; MOHAMED MOHAMED-ESLAM F; MULHERN MATHEW; NORDSTROM FREDRIK LARS; OTHMAN AHMED A; ROZEMA MICHAEL J; BHAGAVATULA LAKSHMI; MARROUM PATRICK J; MAYER PETER T; SHEIKH AHMAD Y; BORCHARDT THOMAS B; KLÜNDER BEN 权利人:ABBVIE INC 摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
专利号:US-11524964-B2 优先权日:2015-10-16 标题:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 发明人:MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; KLÜNDER BEN; PANGAN AILEEN L; SONG IN-HO 权利人:ABBVIE INC 摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
专利号:US-11993605-B2 优先权日:2015-10-16 标 题:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 发明人:MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; KLÜNDER BEN; PANGAN AILEEN L; ANDERSON JACLYN KAY; VOSS JEFFREY W; PADLEY ROBERT J; CAMP HEIDI S 权利人:ABBVIE INC 摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
专利号:CN-101260101-B 优先权日:2007-03-09 标题:Synthesis of intermediate 5,5-dimethyl-1,3-one-2,4-thiolane of bucillamine
1: Horwitz LD. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev. 2003 Summer;21(2):77-90. doi: 10.1111/j.1527-3466.2003.tb00107.x. 19(3):111-112. doi: 10.1002/jgf2.169. 3: Yanagishita T, Tamada Y, Watanabe D. Bucillamine-induced pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1242-3. doi: 10.1111/jdv.12472. Epub 2014 Mar 18. 4(1):122-125. doi: 10.1080/24725625.2019.1673939. Epub 2019 Oct 14. 33(3):793-7. doi: 10.1007/s00296-011-2241-z. Epub 2011 Nov 17. Erratum in: Rheumatol Int. 2013 Oct;33(10):2707. Kawashima, Hironori [corrected to Hirotoshi, Kawashima]. 96(4):870-876. doi: 10.1111/php.13228. Epub 2020 Apr 13. 7: Frank M. Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank. Future Microbiol. 2022 Feb;17(3):157-159. doi: 10.2217/fmb-2021-0277. Epub 2022 Jan 19.
合成参考文献
参考文献:10.4137/ccrep.s5514 摘要:Isozaki T, Yajima N, Sato M, Takahashi R, Wakabayashi K, Miwa Y, Negishi M, Ide H, Kasama T. A case of rheumatoid arthritis with bucillamine-induced yellow nail syndrome initially manifesting as pulmonary disease. Clin Med Insights Case Rep. 2010;3():63–8. 参考文献:10.1007/s10067-011-1810-6 摘要:Ogasawara M, Tamura N, Kageyama M, Onuma S, Kusaoi M, Toyama S, Sekiya F, Matsudaira R, Nawata M, Tada K, Matsushita M, Kempe K, Amano H, Morimoto S, Yamaji K, Takasaki Y. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. Clin Rheumatol. 2012 Feb;31(2):251–7. doi: 10.1007/s10067-011-1810-6. 参考文献:10.1007/s00296-011-1989-5 摘要:Choe JY, Lee H, Jung HY, Park SH, Bae SC, Kim SK. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol Int. 2012 Jun;32(6):1837–42. doi: 10.1007/s00296-011-1989-5.